Invention Grant
US07939503B2 Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA
有权
使用STEAP-1 siRNA减少前列腺癌细胞间通讯
- Patent Title: Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA
- Patent Title (中): 使用STEAP-1 siRNA减少前列腺癌细胞间通讯
-
Application No.: US10861662Application Date: 2004-06-04
-
Publication No.: US07939503B2Publication Date: 2011-05-10
- Inventor: Aya Jakobovits , Soudabeh Etessami , Pia M. Challita-Eid , Juan J. Perez-Villar , Karen J. Morrison , Xiao-Chi Jia , Mary Faris , Jean Gudas , Arthur B. Raitano
- Applicant: Aya Jakobovits , Soudabeh Etessami , Pia M. Challita-Eid , Juan J. Perez-Villar , Karen J. Morrison , Xiao-Chi Jia , Mary Faris , Jean Gudas , Arthur B. Raitano
- Applicant Address: US CA Santa Monica
- Assignee: Agensys, Inc.
- Current Assignee: Agensys, Inc.
- Current Assignee Address: US CA Santa Monica
- Agent Mark T. Kresnak; Shane M. Popp; Ginger R. Dreger
- Main IPC: A61K31/70
- IPC: A61K31/70

Abstract:
Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
Public/Granted literature
- US20050086707A1 Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer Public/Granted day:2005-04-21
Information query